Related Experiment Video
Updated: Aug 15, 2026

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
Published on: October 17, 2025
Vinflunine: a novel antitubulin agent in solid malignancies
Jaafar Bennouna1, Mario Campone, Jean Pierre Delord
1Centre René Gauducheau, Saint-Herblain, France. j-bennouna@nantes.fnclcc.fr
Abstract:
Vinflunine is the first bi-fluorinated, tubulin-targeted agent that was obtained by semisynthesis using super-acidic chemistry, which allowed the selective introduction of two fluorine atoms at the C20' position of vinorelbine. This compound has been selected for clinical development on the basis of promising preclinical activity that warranted a study in patients with a wide spectrum of solid tumours. Clinically significant activity was seen in the Phase II studies for the treatment of bladder, non-small cell lung and breast cancers, thus prompting the initiation of the Phase III trials that are currently ongoing.
Related Concept Videos
Drugs that Stabilize Microtubules
Drugs that Destabilize Microtubules
Inhibitors of Viral Protein Synthesis
Anthelminthic Agents
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists